About Fore Biotherapeutics
Fore Biotherapeutics is a private company based in Philadelphia, Pennsylvania, incorporated in 2022 in Delaware. It has reported $132,489,567 raised in two offerings on Form D since August 2023.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Apr 30, 2025 | May 15, 2025amended Jul 14, 2026 | $70,410,173of $109.6M target | 20 | $3.5M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Aug 9, 2023 | Aug 24, 2023 | $62,079,394of $122.5M target | 20 | $3.1M | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $132,489,567 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Fore Biotherapeutics's Form D filed Jul 14, 2026.
Earlier filings also listed Roberto De Ponti (director, last listed Aug 2023), Michal Silverberg (director, last listed Aug 2023), Meenu Chhabra Karson (director, last listed Aug 2023), Matthew Ros (chief executive officer, president and secretary, director, last listed Aug 2023), Matthew Foy (director, last listed Aug 2023) and Jeff Sacher (chief financial officer, last listed Aug 2023).